YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measur…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Karyopharm Therapeutics and Amgen, as well as update…
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is…
Shares of Evommune EVMN were down 40.2% yesterday after the company announced that the phase IIb study evaluating its oral MRGPRX2 antagonist, EVO756, for treating adult patients with moderate-to-severe chronic spontaneous urticaria (CSU)…
The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies…
Key Points Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. After the sale, Nan Fung's remaining stake of 350,745 shares was valued at approximately $9.3 million -- r…
What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the quar…
Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t…
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Buy from Ho…
Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riskie…
(RTTNews) - Evommune, Inc (EVMN) reported Loss for fourth quarter of -$28.27 million The company's earnings totaled -$28.27 million, or -$1.43 per share. This compares with -$20.73 million, or -$13.58 per share, last year. Evommune, Inc ea…
* Evommune (EVMN) entered into a securities purchase agreement [https://seekingalpha.com/pr/20398817-evommune-announces-125-million-private-placement] to sell ~4.49M shares to a select group of new and existing mutual funds and dedicated h…
Biotech stocks Nektar Therapeutics and Evommune launched Tuesday on positive results for their eczema treatments. Continue Reading
[$10 Banknote Stacking, Green Up Arrow Rise] spawns Evommune (EVMN [https://seekingalpha.com/symbol/EVMN]) added more than ~50% in early trading on Tuesday after the biotech announced a mid-stage trial win for EVO301, its experimental ther…
IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment. Continue Reading
Microscope and test tubes beside a laptop showing a rising chart signal biotech progress and improving stock momentum. Key Points Three biotech names with promising clinical trial data and a history of revenue generation stand out from the…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Goldman Sachs upgraded Chime (CHYM) to Buy…
[IPO Concept with Stock Market Graphs] Evommune (EVMN [https://seekingalpha.com/symbol/EVMN]), a biotechnology startup, has set the price for its initial public offering at $16 per share for approximately 9.4M shares. Trading is anticipate…
NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mast…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Evommune, a biotechnology company making a pair of drugs for immune conditions su…